Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cancer Res. 2019 Nov 1;79(21):5479-5481. doi: 10.1158/0008-5472.CAN-19-2806.
Alpha-emitter radiopharmaceutical therapy (α-RPT) is a treatment modality that is impervious to conventional cellular resistance mechanisms because of the unique properties of the α-particle. Radiobiological studies of α-particle emitters have been few as they require detailed consideration of both biology and physics. Clinical studies of this radiation delivery modality have shown highly promising results in cancers that are resistant to other treatments. The work by Yard and colleagues published in this issue introduces an innovative approach to radiobiological investigations of α-RPT and highlights the specific physics considerations required to properly investigate this multidisciplinary treatment modality..
α 放射药物治疗（α-RPT）是一种治疗方式，由于 α 粒子的独特特性，它不受常规细胞耐药机制的影响。由于需要综合考虑生物学和物理学，因此对 α 粒子发射体的放射生物学研究很少。这种辐射传递方式的临床研究在对其他治疗方法有抵抗力的癌症中显示出非常有前途的结果。Yard 及其同事在本期发表的工作介绍了一种创新的方法来研究 α-RPT 的放射生物学，并强调了正确研究这种多学科治疗方式所需的特定物理考虑因素。
